Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Effects of press-fit biphasic (collagen and HA/βTCP) scaffold with cell-based therapy on cartilage and subchondral bone repair knee defect in rabbits.

Hernigou J, Vertongen P, Chahidi E, Kyriakidis T, Dehoux JP, Crutzen M, Boutry S, Larbanoix L, Houben S, Gaspard N, Koulalis D, Rasschaert J.

Int Orthop. 2018 Jul;42(7):1755-1767. doi: 10.1007/s00264-018-3999-3. Epub 2018 Jun 7.

PMID:
29882123
2.

Osteonecrosis of the Femoral Head: Lipotoxicity Exacerbation in MSC and Modifications of the Bone Marrow Fluid.

Gillet C, Dalla Valle A, Gaspard N, Spruyt D, Vertongen P, Lechanteur J, Rigutto S, Dragan ER, Heuschling A, Gangji V, Rasschaert J.

Endocrinology. 2017 Mar 1;158(3):490-502. doi: 10.1210/en.2016-1687.

PMID:
28359085
3.

Three-dimensional echocardiography of a subtotal mitral valve ring dehiscence.

Timmermans P, Vertongen P, Rega F.

Acta Cardiol. 2014 Apr;69(2):216-7. No abstract available.

PMID:
24783479
4.

Identification of key residues for the binding of glucagon to the N-terminal domain of its receptor: an alanine scan and modeling study.

Prévost M, Vertongen P, Waelbroeck M.

Horm Metab Res. 2012 Oct;44(11):804-9. doi: 10.1055/s-0032-1321877. Epub 2012 Aug 14.

PMID:
22893257
5.

Analysis of the glucagon receptor first extracellular loop by the substituted cysteine accessibility method.

Roberts DJ, Vertongen P, Waelbroeck M.

Peptides. 2011 Aug;32(8):1593-9. doi: 10.1016/j.peptides.2011.06.009. Epub 2011 Jun 15.

PMID:
21704096
6.

Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain.

Prévost M, Vertongen P, Raussens V, Roberts DJ, Cnudde J, Perret J, Waelbroeck M.

J Biol Chem. 2010 Oct 1;285(40):30951-8. doi: 10.1074/jbc.M110.102814. Epub 2010 Jul 20.

7.

Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord.

Lambeng N, Gillard M, Vertongen P, Fuks B, Chatelain P.

Eur J Pharmacol. 2005 Sep 27;520(1-3):70-6.

PMID:
16125696
8.

Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.

Xu L, Depoortere I, Vertongen P, Waelbroeck M, Robberecht P, Peeters TL.

Biochem Pharmacol. 2005 Sep 15;70(6):879-87.

PMID:
16076462
9.

Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling.

Langlet C, Langer I, Vertongen P, Gaspard N, Vanderwinden JM, Robberecht P.

J Biol Chem. 2005 Jul 29;280(30):28034-43. Epub 2005 Jun 2.

10.
11.

Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.

Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P.

Peptides. 2004 Feb;25(2):275-8.

PMID:
15063009
12.

Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines.

Fuks B, Gillard M, Michel P, Lynch B, Vertongen P, Leprince P, Klitgaard H, Chatelain P.

Eur J Pharmacol. 2003 Sep 30;478(1):11-9.

PMID:
14555179
13.

Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain.

Gillard M, Fuks B, Michel P, Vertongen P, Massingham R, Chatelain P.

Eur J Pharmacol. 2003 Sep 30;478(1):1-9.

PMID:
14555178
14.

Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Neuropharmacology. 2003 Jan;44(1):125-31.

PMID:
12559130
15.
16.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Biochem Soc Trans. 2002 Aug;30(4):447-50. Review.

PMID:
12196112
17.

Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations.

Waelbroeck M, Perret J, Vertongen P, Van Craenenbroeck M, Robberecht P.

Biochem Soc Trans. 2002 Aug;30(4):437-41. Review.

PMID:
12196110
18.

Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.

Perret J, Vertongen P, Solano RM, Langer I, Cnudde J, Robberecht P, Waelbroeck M.

Br J Pharmacol. 2002 Aug;136(7):1042-8.

19.

VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells.

Langer I, Vertongen P, Perret J, Cnudde J, Gregoire F, De Neef P, Robberecht P, Waelbroeck M.

Cell Signal. 2002 Aug;14(8):689-94.

PMID:
12020769
20.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Mol Endocrinol. 2002 May;16(5):1089-96.

PMID:
11981043
21.
22.

Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.

Langer I, Perret J, Vertongen P, Waelbroeck M, Robberecht P.

Cell Calcium. 2001 Oct;30(4):229-34.

PMID:
11587546
23.

Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure.

Vertongen P, Solano RM, Juarranz MG, Perret J, Waelbroeck M, Robberecht P.

Peptides. 2001 Sep;22(9):1363-70.

PMID:
11514016
24.

Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.

Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, Waelbroeck M.

Br J Pharmacol. 2001 Aug;133(8):1249-54.

25.

Extensive deep vein thrombosis in a young woman. Case report.

De Backer T, Voet J, De Buyzere M, Vertongen P, T'sjoen G, Duprez D, Clement D.

Int Angiol. 2000 Dec;19(4):369-72.

PMID:
11305739
26.

Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction.

Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, Waelbroeck M.

J Biol Chem. 2001 Jan 12;276(2):1084-8.

27.

Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas.

Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P.

Med Pediatr Oncol. 2000 Jun;34(6):386-93.

PMID:
10842244
28.

Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.

Vertongen P, Schiffmann SN, Gourlet P, Robberecht P.

Ann N Y Acad Sci. 1998 Dec 11;865:412-5. No abstract available.

PMID:
9928040
29.

The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes.

Dewit D, Gourlet P, Amraoui Z, Vertongen P, Willems F, Robberecht P, Goldman M.

Immunol Lett. 1998 Jan;60(1):57-60. No abstract available.

PMID:
9541464
30.

Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues.

Vertongen P, De Clerck P, Fournet JC, Martelli H, Hélardot P, Devalck C, Peeters T, Sariban E, Robberecht P.

Neuropeptides. 1997 Oct;31(5):409-13.

PMID:
9413016
31.

Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo.

Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, Vertongen P, Bergez B, Vandekerckhove Y.

Eur Heart J. 1997 Apr;18(4):643-8.

PMID:
9129896
32.

Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.

Vertongen P, Schiffmann SN, Gourlet P, Robberecht P.

Peptides. 1997;18(10):1547-54.

PMID:
9437715
33.

Development of high affinity selective VIP1 receptor agonists.

Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.

Peptides. 1997;18(10):1539-45.

PMID:
9437714
34.

The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.

Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, Robberecht P.

Peptides. 1997;18(3):403-8.

PMID:
9145428
36.
37.

Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas.

Vertongen P, Devalck C, Sariban E, De Laet MH, Martelli H, Paraf F, Hélardot P, Robberecht P.

J Cell Physiol. 1996 Apr;167(1):36-46.

PMID:
8698838
38.

Characterization of the VIP receptor from SUP T1 lymphoblasts.

Robberecht P, Gourlet P, Vertongen P, Svoboda M.

Adv Neuroimmunol. 1996;6(1):49-57. Review.

PMID:
8790781
39.

Differential alternative splicing of PACAP receptor in pituitary cell subpopulations.

Vertongen P, Velkeniers B, Hooghe-Peters E, Robberecht P.

Mol Cell Endocrinol. 1995 Sep 22;113(2):131-5.

PMID:
8674820
40.

Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis.

van Laethem JL, Deviere J, Resibois A, Rickaert F, Vertongen P, Ohtani H, Cremer M, Miyazono K, Robberecht P.

Gastroenterology. 1995 Jun;108(6):1873-81.

PMID:
7768393
41.

Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours.

Van Laethem JL, Vertongen P, Deviere J, Van Rampelbergh J, Rickaert F, Cremer M, Robberecht P.

Gut. 1995 May;36(5):781-7.

42.

A new transvenous internal cardioverter-defibrillator: implantation technique, complications, and short-term follow-up.

Jordaens L, Vertongen P, Provenier F, Trouerbach JW, Poelaert J, Herregods L.

Am Heart J. 1995 Feb;129(2):251-8.

PMID:
7832096
43.

Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor.

Delporte C, Poloczek P, de Neef P, Vertongen P, Ciccarelli E, Svoboda M, Herchuelz A, Winand J, Robberecht P.

Mol Cell Endocrinol. 1995 Jan;107(1):71-6.

PMID:
7796937
44.

Expression of pituitary adenylate cyclase activating polypeptide and receptors in human brain tumors.

Vertongen P, d'Haens J, Michotte A, Velkeniers B, van Rampelbergh J, Svoboda M, Robberecht P.

Peptides. 1995;16(4):713-9.

PMID:
7479307
45.

Relative quantitative analysis of glucagon receptor mRNA in rat tissues.

Svoboda M, Tastenoy M, Vertongen P, Robberecht P.

Mol Cell Endocrinol. 1994 Nov;105(2):131-7.

PMID:
7859919
46.
47.

Presence of calcitonin gene-related peptide receptors coupled to adenylate cyclase in human gliomas.

Robberecht P, De Neef P, Woussen-Colle MC, Vertongen P, De Witte O, Brotchi J.

Regul Pept. 1994 Jun 16;52(1):53-60.

PMID:
7972932
48.

Prolonged monitoring for detection of symptomatic arrhythmias after slow pathway ablation in AV-nodal tachycardia.

Jordaens L, Vertongen P, Verstraeten T.

Int J Cardiol. 1994 Mar 15;44(1):57-63.

PMID:
8021051
49.

Chromogranin A(210-301) is the major form of pancreastatin-like material in human gut extracts and endocrine tumors.

Woussen-Colle MC, Lingier P, Vertongen P, Vandermeers-Piret MC, Vandermeers A, Robberecht P.

Peptides. 1994;15(5):869-74.

PMID:
7984507
50.

Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors.

Robberecht P, Woussen-Colle MC, Vertongen P, De Neef P, Hou X, Salmon I, Brotchi J.

Peptides. 1994;15(4):661-5.

PMID:
7937342

Supplemental Content

Loading ...
Support Center